The recommended treatment for ST elevation acute myocardial infarction (STEMI) is early PCI, typically stenting. However, stent implantation always involves the risk of intravascular complications, such as stent thrombosis or restenosis. Sometimes stable flow is restored to the target vessel after initial PCI and we can omit stenting when there is no angiographically significant residual<a href="https://solaci.org/en/2022/04/04/stemi-can-we-omit-stenting/" title="Read more" >...</a>
While the ideal treatment for coronary bifurcation is provisional stenting, this can be associated with side branch occlusion, which leads to severe adverse events. To prevent this complication, several treatments have been proposed. One of them is wire jailing at side branch before stent implantation in the main vessel. However, the actual benefit of this<a href="https://solaci.org/en/2022/03/29/wire-jailing-at-side-branch-to-prevent-occlusion-after-main-vessel-stenting-should-it-be-the-standard-of-care/" title="Read more" >...</a>
Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization<a href="https://solaci.org/en/2022/03/21/ticagrelor-monotherapy-after-3-months-is-the-current-strategy-worth-changing/" title="Read more" >...</a>
Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12 months. However, in patients with certain clinical<a href="https://solaci.org/en/2022/03/21/abbreviated-dapt-in-acs-the-end-of-clopidogrel-monotherapy/" title="Read more" >...</a>
The mortality of ST-segment elevation acute coronary syndromes (STEACS) has decreased thanks to improved reperfusion times (fibrinolysis or primary angioplasty), so that, in daily practice, there is a greater number of patients with stable acute myocardial infarction (AMI). This clinical stability and a low rate of complications raise the question of whether performing triage is<a href="https://solaci.org/en/2022/03/16/zwolle-score-can-a-risk-score-decide-where-steacs-patients-should-stay/" title="Read more" >...</a>
Currently, edge-to-edge therapy with MitraClip has demonstrated efficacy and safety for the treatment of patients with degenerative or functional mitral regurgitation who are at high risk for surgery. However, device-related complications are still present—though their frequency is subsiding due to greater experience, 3D doppler echocardiography development, and technological advancements: loss of leaflet insertion (LLI), single<a href="https://solaci.org/en/2022/03/10/mitraclip-failure-what-should-we-do/" title="Read more" >...</a>
This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>
This registry of daily clinical practice suggests that this specifically designed double-mesh carotid stent is safe and associated with a minimal and acceptable occurrence of neurological events up to 12 months of follow-up. This double-mesh stent has already been tested, and its short- and long-term efficacy has been proven. However, more recent data have challenged the<a href="https://solaci.org/en/2021/09/27/one-year-of-successful-carotid-artery-stenting-with-the-cguard-device/" title="Read more" >...</a>
✔️ Watch again the session on Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 04:55 – Thromboembolic Complications in COVID – José Ceresetto 27:59 – Global Registry of Acute Myocardial Infarction of Primary PCI in COVID Era – Giuseppe De Luca 53:36 – Infectious Disease Care in<a href="https://solaci.org/en/2021/09/21/solaci-caci-2021-cardiovascular-disease-management-and-cath-lab-during-the-covid-19-pandemic/" title="Read more" >...</a>
What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could serve as a new protection against cardiovascular disease. During five years (the total research time), this study compared individuals who lived in the lowest tercile of “greenness” with those who lived in the highest tercile (i.e., those who<a href="https://solaci.org/en/2021/09/03/esc-2021-greenness-surprising-new-protective-factor-against-cardiovascular-disease/" title="Read more" >...</a>